MARKET

MIRM

MIRM

Mirum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.62
-0.01
-0.07%
Opening 15:51 08/05 EDT
OPEN
14.63
PREV CLOSE
14.63
HIGH
14.95
LOW
14.30
VOLUME
46.63K
TURNOVER
--
52 WEEK HIGH
27.43
52 WEEK LOW
13.90
MARKET CAP
445.23M
P/E (TTM)
-2.9904
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 7h ago
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Benzinga · 4d ago
Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
FOSTER CITY, Calif., July 29, 2021--Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
Business Wire · 6d ago
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28)
Benzinga · 07/29 12:15
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 07/27 11:48
Mirum Pharma Out-Licenses Maralixibat Rights To GC Pharma in South Korea
Benzinga · 07/27 10:59
Mirum Pharmaceuticals to Grant GC Pharma Sole Rights to Commercialize Liver Disease Drug in South Korea
MT Newswires · 07/27 05:27
Mirum Pharma inks maralixibat development deal for rare liver disease in South Korea
Mirum Pharmaceuticals (MIRM) and GC Pharma have entered into an exclusive licensing agreement for development and commercialization of maralixibat in South Korea.Under the terms of the agreement, GC Pharma has obtained the
Seekingalpha · 07/27 04:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MIRM. Analyze the recent business situations of Mirum Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MIRM stock price target is 50.29 with a high estimate of 77.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 72
Institutional Holdings: 21.63M
% Owned: 71.01%
Shares Outstanding: 30.45M
TypeInstitutionsShares
Increased
22
969.60K
New
8
85.81K
Decreased
16
472.02K
Sold Out
19
1.14M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.17%
Pharmaceuticals & Medical Research
+0.78%
Key Executives
Chairman/Director
Michael Grey
President/Chief Executive Officer/Co-Founder/Director
Christopher Peetz
Chief Financial Officer/IR Contact Officer
Ian Clements
Chief Operating Officer
Peter Radovich
Chief Scientific Officer
Pamela Vig
Other
Lara Longpre
Other
Edwin Tucker
Director
Carol Brosgart
Independent Director
Tiba Aynechi
Independent Director
Laura Brege
Independent Director
Laurent Fischer
Independent Director
Patrick Heron
Independent Director
Edward Mathers
Independent Director
Niall O' Donnell
No Data
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a range of orphan liver diseases. The Company initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis (PFIC), and Alagille syndrome (ALGS). It has commenced enrollment in the Phase III clinical trial in PFIC and planning to initiate a Phase III clinical trial in ALGS. The Company is developing volixibat for the treatment of adult patients with cholestatic liver diseases including primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy (ICP) and primary biliary cholangitis (PBC).

Webull offers kinds of Mirum Pharmaceuticals Inc stock information, including NASDAQ:MIRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MIRM stock methods without spending real money on the virtual paper trading platform.